PSMA6 and cystic fibrosis: Post-transplant survival for IPF patients (median 4.5 years) was significantly (P ≤ 0.001) lower compared to patients with pre-transplant diagnoses of cystic fibrosis (CF; 7.8 years), chronic obstructive pulmonary disease (COPD; 5.4 years), or Alpha-1 - antitrypsin deficiency (6.3 years) [12].